Advanced Therapies Summit
The Advanced Therapies Summit is a gathering of top executives and clinical researchers from across Europe and the US. This one-day meeting features interactive talks, group discussion and extensive networking opportunities.
Paris, France

Register Today!
Advanced Therapies Summit
This one-day meeting will bring together top executives and clinical researchers from both the EU and US advanced therapies communities to foster discussion aimed at furthering the field as a whole. The program will feature high-level, interactive talks with large pharma leaders on the role their corporations play in advancing the field. Additionally, experts in translational medicine as well as regulatory and reimbursement thought-leaders will guide discussions focused on broadening the understanding of the advanced therapies sector, and the work needed to be done to continue its growth and success. This meeting will consist exclusively of group discussion led by selected experts and will include extensive networking opportunities with leading international advanced therapies companies.

*Pre-registration for this event has closed. On-site registration will be available beginning at 8:30am on Thursday, March 12.

Program Agenda
Thursday, March 12, 2015
8:30am | Registration, Breakfast & Networking

9:00am | Program Introduction & Welcome Remarks
Morrie Ruffin, Managing Director, Alliance for Regenerative Medicine
Michael Werner, Executive Director, Alliance for Regenerative Medicine

9:15am | State of the Advanced Therapies Industry Remarks

Edward Lanphier, Chairman, Alliance for Regenerative Medicine; President & CEO, Sangamo BioSciences

9:30am | Roundtable I: Cell Therapy Commercialization
Discussion Leaders:

Eduardo Bravo, CEO, TiGenix
Olav Hellebo, CEO, ReNeuron
Georges Rawadi, Ph.D., VP Business Development, Cardio3 BioSciences
Timothy Schroeder, CEO, CTI Clinical Trial & Consulting Services
Kunihiko Suzuki, Vice Chairman of Forum for Innovative Regenerative Medicine (FIRM); Member of the Board & Chief Business Officer, MEDINET

10:45am | Morning Break

11:00am | Roundtable II: Gene Therapy in Europe & the U.S.
Discussion Leaders:
Karen Aiach, President & CEO, Lysogene
Jean-Philippe Combal, Pharm. D., Ph.D., COO, GenSight Biologics

Peter Nolan, Chief Business Officer, Oxford BioMedica
Frédéric Revah, Ph.D., CEO, Genethon

12:15pm | Lunch & Networking

1:30pm | Roundtable III: Big Pharma's Evolving Advanced Therapies Outlook
Discussion Leaders:
Stewart Abbot, Ph.D., Executive Director, Integrative Research, Celgene Cellular Therapeutics

Nicolas Koebel, Global Commercial Lead, GSK Rare Diseases
Deborah Van Riet, Director, Future Therapeutics & Technologies, Integrated Science & Technology, AbbVie

2:45pm | Afternoon Break

3:00pm | Roundtable IV: The Role of Europe’s Major Cell & Gene Therapy Research Institutions in Enabling Effective Clinical & Commercial Translation
Discussion Leaders:
Matthew Durdy, Chief Business Officer, Cell Therapy Catapult
Annamaria Merico, Ph.D., Intellectual Property Manager, Fondazione Telethon
Thomas Tradler, Ph.D., Head of Business Development & Patent Management, Fraunhofer Institute for Cell Therapy and Immunology
Marc Turner, MB, Ch.B., Ph.D., Professor, Cellular Therapy, University of Edinburgh MRC Centre for Regenerative Medicine; Medical Director, Scottish National Blood Transfusion Service (SNBTS)

4:15pm | Closing Discussion: ARM's Agenda for Europe in 2015
Discussion Leaders:
Michael Hunt, Co-Chair, European Section, Alliance for Regenerative Medicine; Chief Financial Officer, ReNeuron
Alexander Vos, Co-Chair, European Section, Alliance for Regenerative Medicine; CEO, PharmaCell

4:45pm | Networking Reception

Cost of Attendance
ARM Members: 550

Paris Marriott Rive Gauche Hotel & Conference Center
17 Boulevard Saint Jacques
Paris 75014 France

*Please note that there is not a discounted room block available for this event. Attendees are asked to make their own hotel reservations. 

Chelsey Hathaway
Coordinator, Events & Committees